Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
1.26M
-
Shares change
-
+438K
-
Total reported value, excl. options
-
$15M
-
Value change
-
+$4.35M
-
Number of buys
-
23
-
Number of sells
-
-10
-
Price
-
$11.93
Significant Holders of GYRE THERAPEUTICS, INC. - COM (GYRE) as of Q2 2024
36 filings reported holding GYRE - GYRE THERAPEUTICS, INC. - COM as of Q2 2024.
GYRE THERAPEUTICS, INC. - COM (GYRE) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.26M shares
.
Largest 10 shareholders include BlackRock Inc. (499K shares), GEODE CAPITAL MANAGEMENT, LLC (260K shares), VANGUARD GROUP INC (232K shares), STATE STREET CORP (96.1K shares), NORTHERN TRUST CORP (32.7K shares), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (23.1K shares), WINTON GROUP Ltd (18.5K shares), Bank of New York Mellon Corp (18.3K shares), RENAISSANCE TECHNOLOGIES LLC (13.9K shares), and MARSHALL WACE, LLP (10.7K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.